Holen Sie sich die Stockscreener-App
3.74
2.75%
0.10
Handel nachbörslich:
3.74
Schlusskurs vom Vortag:
$3.64
Offen:
$3.67
24-Stunden-Volumen:
758.75K
Relative Volume:
0.76
Marktkapitalisierung:
$219.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-1.9894
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
+3.60%
1M Leistung:
+16.51%
6M Leistung:
-59.74%
1J Leistung:
-26.67%
1-Tages-Spanne:
$3.585
$3.795
1-Wochen-Bereich:
$3.34
$3.81
52-Wochen-Spanne:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Vergleichen Sie OMER mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
3.74 | 211.52M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
What analysts say about Omeros Corporation stockDynamic capital growth - jammulinksnews.com
What drives Omeros Corporation stock priceTremendous wealth creation - jammulinksnews.com
Why Omeros Corporation stock attracts strong analyst attentionAnalyst Grade Signals - Newser
Is Omeros Corporation a good long term investmentSky-high profits - PrintWeekIndia
Omeros Corporation Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
How Omeros Corporation stock performs during market volatilityStrategic High Profit Opportunities - beatles.ru
what makes omeros corporation stock price move sharplyFree Access to Community - Newser
FY2027 Earnings Forecast for Omeros Issued By HC Wainwright - Defense World
What makes Omeros Corporation stock price move sharplyWatchlist Winner Update - Newser
Omeros Corporation (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Wealth Enhancement Advisory Services LLC Takes $579,000 Position in Omeros Corporation (NASDAQ:OMER) - Defense World
Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost - MSN
Both retail investors who control a good portion of Omeros Corporation (NASDAQ:OMER) along with institutions must be dismayed after last week's 12% decrease - simplywall.st
Omeros shareholders elect directors and approve executive pay at annual meeting - Investing.com
Omeros stock maintains Buy rating at H.C. Wainwright on EU submission - Investing.com
Omeros (NASDAQ:OMER) Downgraded by Wall Street Zen to “Sell” - Defense World
Omeros' Narsoplimab: A Lifeline for TA-TMA Patients and a Regulatory Crossroads - AInvest
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA | OMER Stock News - GuruFocus
Omeros (OMER) Eyes European Approval for Key Drug Narsoplimab | OMER Stock News - GuruFocus
Omeros Announces Webcast Details for Annual Meeting of Shareholders - The Joplin Globe
Ratios Revealed: Decoding Omeros Corporation (OMER)’s Financial Health - DWinneX
Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
What is HC Wainwright’s Forecast for Omeros FY2025 Earnings? - Defense World
HC Wainwright Predicts Omeros’ Q2 Earnings (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Now Covered by Analysts at HC Wainwright - Defense World
Cantor Fitzgerald Comments on Omeros FY2026 Earnings - Defense World
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga
Trend Tracker for (OMER) - news.stocktradersdaily.com
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OME - GuruFocus
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OMER Stock News - GuruFocus
HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target - MarketScreener
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval - GuruFocus
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval | OMER Stock News - GuruFocus
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - mx.advfn.com
Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - Defense World
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 - mx.advfn.com
OMEROmeros Corporation Reports First Quarter 2025 Financial Results - mx.advfn.com
Squarepoint Ops LLC Has $316,000 Stake in Omeros Co. (NASDAQ:OMER) - Defense World
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):